Dr. Crystal Proud, M.D
NPI: 1013159177
Total Payments
$889,381
2024 Payments
$263,283
Companies
18
Transactions
956
Payment Breakdown by Category
Consulting$476,468 (53.6%)
Other$282,015 (31.7%)
Travel$72,159 (8.1%)
Research$26,382 (3.0%)
Food & Beverage$23,713 (2.7%)
Education$8,645 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $476,468 | 112 | 53.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $235,914 | 155 | 26.5% |
| Travel and Lodging | $72,159 | 187 | 8.1% |
| Honoraria | $46,101 | 23 | 5.2% |
| Unspecified | $26,382 | 26 | 3.0% |
| Food and Beverage | $23,713 | 431 | 2.7% |
| Education | $8,645 | 22 | 1.0% |
Payments by Type
General
$862,999
930 transactions
Research
$26,382
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sarepta Therapeutics, Inc. | $392,398 | 215 | $0 (2024) |
| Biogen, Inc. | $374,977 | 566 | $0 (2024) |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $62,983 | 83 | $0 (2024) |
| F. Hoffmann-La Roche AG | $19,106 | 23 | $0 (2024) |
| Hoffmann-La Roche Limited | $9,656 | 6 | $0 (2024) |
| AveXis | $8,469 | 13 | $0 (2019) |
| PFIZER INC. | $8,358 | 6 | $0 (2024) |
| Medtronic, Inc. | $6,200 | 7 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,557 | 4 | $0 (2024) |
| Genentech USA, Inc. | $2,416 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $263,283 | 164 | Sarepta Therapeutics, Inc. ($205,319) |
| 2023 | $158,163 | 173 | Sarepta Therapeutics, Inc. ($106,666) |
| 2022 | $98,745 | 118 | Sarepta Therapeutics, Inc. ($53,852) |
| 2021 | $67,255 | 68 | Biogen, Inc. ($50,691) |
| 2020 | $71,861 | 85 | Biogen, Inc. ($33,792) |
| 2019 | $90,361 | 154 | Biogen, Inc. ($80,873) |
| 2018 | $99,399 | 135 | Biogen, Inc. ($92,953) |
| 2017 | $40,313 | 59 | Biogen, Inc. ($35,891) |
All Payment Transactions
956 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $306.87 | Research |
| Study: A Gene Delivery Study to Evaluate the Safety of and Expression From SRP-9001 in Duchenne Muscular Dystrophy (DMD) (ENDEAVOR) | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $135.97 | Research |
| Study: A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK) | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $103.34 | Research |
| Study: A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK) | ||||||
| 12/19/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $665.00 | General |
| 12/19/2024 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $119.00 | General |
| 12/19/2024 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $94.25 | General |
| 12/19/2024 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $47.73 | General |
| 12/19/2024 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $39.85 | General |
| 12/19/2024 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $36.00 | General |
| 12/18/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,801.25 | General |
| 12/18/2024 | Biogen, Inc. | SPINRAZA (Biological), SKYCLARYS, ZURZUVAE | Consulting Fee | Cash or cash equivalent | $2,226.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | SPINRAZA (Biological), SKYCLARYS | Food and Beverage | In-kind items and services | $94.65 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,660.00 | General |
| 11/22/2024 | ITF Therapeutics LLC | — | Food and Beverage | In-kind items and services | $20.13 | General |
| 11/21/2024 | ITF Therapeutics LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| 11/21/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Education | Cash or cash equivalent | $31.10 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Education | Cash or cash equivalent | $13.49 | General |
| Category: NEUROLOGY | ||||||
| 11/14/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $13,466.25 | General |
| 11/14/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $665.00 | General |
| 11/13/2024 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,392.00 | General |
| Category: Neurology | ||||||
| 11/13/2024 | Biogen, Inc. | SPINRAZA (Biological), SKYCLARYS | Food and Beverage | In-kind items and services | $118.43 | General |
| Category: Neurology | ||||||
| 11/06/2024 | Biogen, Inc. | SPINRAZA (Biological), SKYCLARYS | Food and Beverage | In-kind items and services | $120.01 | General |
| Category: Neurology | ||||||
| 11/04/2024 | Biogen, Inc. | SPINRAZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| Category: Neurology | ||||||
| 11/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 10/31/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,310.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec | Biogen, Inc. | $8,000 | 1 |
| Elevate-TDD | Medtronic, Inc. | $6,200 | 7 |
| US-SMG-17-11141 (CST): Characterization of SMA in US Hospitals (consultant Proud) | Biogen, Inc. | $4,500 | 1 |
| Research Medical Writing and Publication Support | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $3,164 | 1 |
| A Gene Delivery Study to Evaluate the Safety of and Expression From SRP-9001 in Duchenne Muscular Dystrophy (DMD) (ENDEAVOR) | F. Hoffmann-La Roche AG | $1,321 | 4 |
| ENVISION, a Phase 3, randomized trial evaluating the safety and efficacy of delandistrogene moxeparvovec in Duchenne muscular dystrophy: Study design | F. Hoffmann-La Roche AG | $1,063 | 1 |
| Systemic Gene Delivery Clinical Trial for Duchenne Muscular Dystrophy (DMD) | F. Hoffmann-La Roche AG | $651.42 | 3 |
| A GENE DELIVERY STUDY TO EVALUATE THE SAFETY OF AND EXPRESSION FROM SRP-9001 IN DUCHENNE MUSCULAR DYSTROPHY DMD ENDEAVOR | F. Hoffmann-La Roche AG | $537.07 | 1 |
| Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 Primary results | F. Hoffmann-La Roche AG | $473.19 | 3 |
| A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK) | F. Hoffmann-La Roche AG | $239.31 | 2 |
| A Phase 3 Multinational Randomized Double-Blind Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK) | F. Hoffmann-La Roche AG | $232.52 | 2 |
About Dr. Crystal Proud, M.D
Dr. Crystal Proud, M.D is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2009. The National Provider Identifier (NPI) number assigned to this provider is 1013159177.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Crystal Proud, M.D has received a total of $889,381 in payments from pharmaceutical and medical device companies, with $263,283 received in 2024. These payments were reported across 956 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($476,468).
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Other Specialties Neuromuscular Medicine, Neurology with Special Qualifications in Child Neurology
- Location Norfolk, VA
- Active Since 04/03/2009
- Last Updated 10/19/2015
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1013159177
Products in Payments
- SPINRAZA (Biological) $301,891
- ZOLGENSMA (Biological) $67,342
- Spinraza (Biological) $23,161
- EXONDYS 51 (Drug) $10,787
- SKYCLARYS (Drug) $8,692
- Exondys 51 (Drug) $6,106
- ZOLGENSMA (Drug) $5,514
- TECFIDERA (Drug) $5,236
- Evrysdi (Drug) $4,871
- Elevidys (Drug) $223.54
- Qelbree (Drug) $216.82
- EMFLAZA (Drug) $149.49
- QALSODY (Drug) $135.40
- TYSABRI (Biological) $67.41
- VNS - Sentiva (Device) $47.11
- AGAMREE (Drug) $44.59
- QELBREE (Drug) $36.31
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $33.90
- The Vest System 205 Acute Care (Device) $24.11
- (820) Cholbam (Drug) $0.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Norfolk
Ludwig Frank, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $6,000
Neurology with Special Qualifications in Child Neurology $6,000
Dr. Ryan Williams, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $2,860
Neurology with Special Qualifications in Child Neurology $2,860
Dr. Georg Dahl, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $2,162
Neurology with Special Qualifications in Child Neurology $2,162
Ralph Northam, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $1,423
Neurology with Special Qualifications in Child Neurology $1,423
Charles Adams, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $377.18
Neurology with Special Qualifications in Child Neurology $377.18
Svinder Toor, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $139.11
Neurology with Special Qualifications in Child Neurology $139.11